http://www.247wallst.com/2007/11/geron-positive-.html
<p>By Jon C. Ogg, Nov. 7, 2007 (247wallst.com)- Geron Corp. (NASDAQ:GERN) is trading up in pre-market activity on news that would have been much more eagerly received back in the emergence of stem cell news. Geron announced that data shows its human embryonic stem cell based therapeutic candidate for spinal cord injury GRNOPC1 survives and exhibits durable and robust human remyelination in spinal cord-injured rats. The duration was for at least nine months following a single injection…</p>